Leadership & Pay ·
Kura Oncology, Inc. entered into amended and restated executive employment agreements with Chairman, President and CEO…
KURAKura Oncology, Inc.
Kura Oncology, Inc. entered into amended and restated executive employment agreements with Chairman, President and CEO Troy E. Wilson, CCO Brian Powl, and COO Kathleen Ford to modify severance provisions. Under the new terms, executives receive enhanced double-trigger change-in-control benefits if terminated without cause or for good reason within 59 days prior to or 18 months after a corporate transaction. Dr. Wilson is entitled to 24 months of base salary and 200% of target bonus, while Messrs. Powl and Ms. Ford receive 18 months of base salary and 150% of target bonus. All agreements include full acceleration of equity vesting and extended COBRA coverage. Kura Oncology operates in the biotechnology industry, focusing on the discovery and development of small molecule therapies for cancer.